Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S0BJ
|
|||
| Former ID |
DIB013862
|
|||
| Drug Name |
Tebentafusp
|
|||
| Synonyms |
IMCgp100
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Gastric cancer [ICD-11: 2B72] | Approved | [1] | |
| Cutaneous melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [2], [3] | ||
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [4], [5] | ||
| Company |
Immunocore
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Melanocytes lineage-specific antigen GP100 (PMEL) | Target Info | Modulator | [6] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761228. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | ClinicalTrials.gov (NCT03070392) Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma | |||
| REF 5 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 6 | Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.